In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 33, No. 3_suppl ( 2015-01-20), p. 95-95
Abstract:
95 Background: The Project HOPE (High-tech Omics-based Patient Evaluation) is an ongoing comprehensive platform that analyzes genome and transcriptome of fresh surgical specimens and blood samples obtained from cancer patients using whole-exome sequencing (WES, AmpliSeq Exome kit, Life Technology) and gene expression profiling (GEP, DNA microarray, Agilent Technologies). The research plan was approved by institutional review board (IRB) in Shizuoka Cancer Center, and total number of patients evaluated in this plan was about 3000 during the 3-year period of the research. Here, we focused on gastric cancer to investigate its characteristic profile. Methods: Tumor sample and peripheral blood was obtained from a total of 19 gastric cancer patients. At the initial stage of the study, the known mutation sites were analyzed by the WES, and expression level of cancer-related genes was evaluated by GEP. Results: Fourteen patients out of 19 patients (74 %) were categorized as advanced gastric cancer. The patients with single nucleotide variations (SNVs) in tumor protein P53 (TP53) accounted for 37% (7/19), and 21% (4/19) of patients had multiple SNVs in the known mutation sites. Furthermore, in two patients with gene amplification of ERBB2 or EGFR, mRNA expression corresponding these genes was markedly up-regulated. Conclusions: WES and GEP analyses may play an important role in interpretation of genetic changes of cancer tissues and personalized medicine.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2015.33.3_suppl.95
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2015
detail.hit.zdb_id:
2005181-5